OncoMatch/Clinical Trials/NCT05357794
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Is NCT05357794 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Brentuximab vedotin for mycosis fungoides.
Treatment: Brentuximab vedotin — To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy \[ULD-TSEBT\]) in combination with brentuximab vedotin can help to control mycosis fungoides
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD30 expression ≥ 1% (≥ 1%)
mycosis fungoides expressing at least 1% CD30
Disease stage
Required: Stage I, II, III, IV
Performance status
ECOG 0–3(Limited self-care)
Lab requirements
Blood counts
absolute WBC > 1000, platelets > 50K
Kidney function
No severe renal impairment (creatinine clearance [CrCL] <30 mL/min)
Liver function
No moderate or severe hepatic impairment (Child-Pugh B or C)
absolute WBC > 1000, platelets > 50K; Severe renal impairment (creatinine clearance [CrCL] <30 mL/min) [excluded]; Moderate or severe hepatic impairment (Child-Pugh B or C) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify